Quantum News
Sign InSign Up
Back to News
research

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Bausch + Lomb executives presented updates on its glaucoma pipeline during a March 2026 investor call, highlighting two key innovations: BL-1107 (a novel alpha-2b agonist) and ELIOS (an excimer laser treatment). BL-1107, a pharmaceutical candidate, targets intraocular pressure reduction via a unique alpha-2b receptor mechanism, positioning it as a potential first-in-class therapy for glaucoma patients resistant to current treatments. ELIOS, a minimally invasive excimer laser device, aims to improve trabecular meshwork outflow with precision, offering an alternative to traditional surgical interventions for glaucoma management. Company leaders, including CEO Brent Saunders and CMO Yehia Hashad, emphasized the $8B+ glaucoma market opportunity, citing unmet needs in both pharmaceutical and surgical segments. The call included clinical development timelines, with BL-1107 advancing toward Phase 3 trials and ELIOS preparing for regulatory submissions, signaling accelerated progress in Bausch + Lomb’s ophthalmic innovation strategy.
AI Audio Summary
0:00 / 0:00
Click to play
8377ec08-9e06-4a8f-b6b0-006509aa5665.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.09K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios March 23, 2026 1:30 PM EDT Company Participants Yehia Hashad - Executive VP of Research & Development and Chief Medical officerMayssa Attar - Senior VP of Pharmaceutical & Head of Consumer R&DKelly SwaimCathleen McCabeAndrew Stewart - President of Global Pharmaceuticals & International ConsumerBrenton L. Saunders - CEO & Chairman Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Operator Please note, today's call is being recorded. Larry BiegelsenWells Fargo Securities, LLC, Research Division Good afternoon. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. Welcome to the next call in our 2026 MedTech Innovation Spotlight Call Series. I'm pleased to have the management team from Bausch + Lomb. Speakers for this call will include Dr. Yehia Hashad, Executive Vice President of R&D and Chief Medical Officer; Dr. Mayssa Attar, Senior Vice President of Pharmaceuticals and Consumer R&D; Dr. Kelly Swaim, Senior Vice President of Surgical R&D; and Dr. Cathleen McCabe, an ophthalmologist and cataract surgeon who is a Strategic Medical Adviser to Bausch + Lomb. Additional participants from the company include Brent Saunders, Chairman and CEO; Sam Eldessouky, Executive Vice President and CFO; and Andrew Stewart, Global Pharmaceuticals and International Consumer President. On today's call, we will focus on Bausch + Lomb's exciting glaucoma pipeline, specifically BL-1107, its alpha-2b agonist and ELIOS, an excimer laser for glaucoma. We'll start with a presentation by the company that summarizes the overall market and opportunity, the products and their Mechanism of Action and development updates. We'll then proceed to Q&A. And if anyone has a question they want me to ask on their behalf, please e-mail it to me. So everyone on the line from Bausch + Lomb, thank you for the opportunity to host this call. At this

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.